10-Q · May 14, 2026
Moleculin Biotech reported zero revenue for Q1 2026, with a diluted EPS of -47.25, significantly worse than the previous year. Management emphasized the urgency for financial resources amid ongoing clinical trials,…
Earnings analysis · 10-Q
MBRX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Moleculin reported no revenue and continued operating losses, with Q2 2026 operating expenses rising 32% year over year to $7.561 million and operating cash burn reaching $12.768 million for the first six months.…
Read full summary
Moleculin reported no revenue and continued operating losses, with Q2 2026 operating expenses rising 32% year over year to $7.561 million and operating cash burn reaching $12.768 million for the first six months. Reported net loss and EPS improved versus Q2 2025 because that period included substantial warrant-related losses, while underlying R&D spending increased materially to support the MIRACLE trial. Clinical data and enrollment progress were encouraging, but the company disclosed substantial doubt about continuing as a going concern, needs approximately $8 million of additional funding into Q2 2027, and faces Nasdaq bid-price and significant dilution risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.4
- Segment
- Single reportable segment—development and commercialization of drug products: revenue $0; Q2 2026 operating expenses $7.561 million and loss from operations $7.561 million.
What stood out
-
MIRACLE interim efficacy favored Annamycin
Preliminary unblinded MIRACLE results for the first 45 subjects showed complete remission rates of 43% and 36% in the two Annamycin cohorts versus 12% for control; composite complete remission rates were 50% and 57% versus 29% for control.
-
MIRACLE enrollment nearing completion
MIRACLE enrollment reached 76 of 90 subjects as of August 6, 2026, and management expects to treat the 90th subject in September 2026. Comprehensive Part A unblinding is anticipated in the December 2026 to February 2027 timeframe.
-
Reported loss and EPS improved year over year
Q2 2026 net loss improved to $7.635 million from $17.809 million in Q2 2025, while diluted loss per share improved to $1.40 from $28.68. The comparison benefited substantially from the prior-year $10.352 million loss on issuance of warrant liabilities.
-
August financing extended cash runway
The company raised approximately $9.3 million gross in an August public offering, issuing 12,376,667 shares or pre-funded warrants and Series I warrants covering up to 37,130,001 shares. Management said the financing should extend planned operations into Q1 2027.
-
Cardiac-safety profile remains differentiated
Annamycin pooled cardiac-safety data covered 90 patients across five clinical trials; among 78 patients with source-verified pre- and post-treatment ejection-fraction assessments, no patients met criteria for clinically significant left-ventricular dysfunction.
What to watch
-
Insufficient liquidity and going-concern doubt
Cash and cash equivalents declined to $7.262 million at June 30, 2026 from $8.878 million at December 31, 2025. Management stated that $7.3 million of cash on hand was not sufficient to fund planned operations for at least one year from issuance of the filing, creating substantial doubt about going-concern status.
-
Rising clinical spend accelerates burn
Operating cash usage increased to $12.768 million in the first six months of 2026 from $10.146 million in the prior-year period, while R&D expense increased to $10.828 million from $7.036 million, primarily due to MIRACLE clinical-trial and related development costs.
-
Additional financing and dilution required
The company said it must seek approximately $8 million of additional funding to support MIRACLE and operations into Q2 2027. The August Series I warrants covering up to 37,130,001 shares include an exercise-price floor of $0.21, creating substantial potential dilution and financing overhang.
-
Nasdaq bid-price compliance risk
The company is not currently compliant with Nasdaq's bid-price requirement: its closing share price has been below $1.00 since July 31, 2026. Because the company completed a 1-for-25 reverse stock split on December 1, 2025, it may not be eligible for a standard 180-day compliance period if delisting proceedings begin.
-
Operating liabilities increased
Accounts payable increased to $4.337 million from $3.508 million and accrued expenses increased to $4.976 million from $3.346 million between December 31, 2025 and June 30, 2026, indicating increased unpaid operating obligations as liquidity tightens.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that cash on hand plus the $9.3 million gross August financing is expected to fund planned operations into Q1 2027, but the company must seek approximately $8 million of additional funding to support MIRACLE and operations into Q2 2027.
Earlier filings 4
10-K · March 18, 2026
Moleculin Biotech is a clinical-stage biotech focused on Annamycin, a “next‑generation” anthracycline currently being evaluated in the global MIRACLE pivotal Phase 2B/3 trial (MB-108). The company reports encouraging…
10-Q · May 13, 2025
Moleculin reported Q1 2025 net loss of $6.436M versus $4.970M in Q1 2024; EPS improved to $(0.69) from $(2.02) due to a large increase in weighted average shares to 9,343,771. Revenue remained $0 for the quarter. Cash…
10-Q · November 8, 2024
Moleculin reported no revenue and a Q3 net loss of $10.6M (EPS -$2.85) vs $5.6M (EPS -$2.82) in Q3 2023; operating expenses rose to $7.135M from $5.947M driven by R&D. Cash declined to $9.405M at September 30, 2024 from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.